Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 958-964

  Brown, Barbara A ^a,b   Griffith, David E ^a   Girard, William ^a   Levin, Jeffrey ^a   Wallace Jr , Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UTHCT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; DOXYCYCLINE; RIFABUTIN; RIFAMPICIN; SULFAMETHOXAZOLE; TUBERCULOSTATIC AGENT;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG HALF LIFE; DRUG MIXTURE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INSOMNIA; LIVER FIBROSIS; LUNG INFECTION; MALAISE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; VERTIGO;

EID: 0030944540     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.958     Document Type: Article

References (14)

1. Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-41.
2. Wallace RJ Jr, Brown BA, Griffith DE. Drag intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-21.
3. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153:1766-72.
4. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
5. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infections in patients with the immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis 1991;144:564-9.
6. Dautzenberg B, Saint Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993;153:368-72.
7. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905-11.
8. Dautzenberg B, Piperao D, Diot P, Truffot-Pernot C, Chauvin J-P, the Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995;107:1035-40.
9. Koletar S. Azithromycin (AZ) improves survival in AIDS patients with disseminated Mycobacterium avium complex (MAC) [abstract no 1199]. In: Program and abstracts of the 34th Interscience Conference on Anti- microbial Agents and Chemotherapy (Orlando, Florida). Washington, DC: American Society for Microbiology, 1994:211.
10. Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium arium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
11. Griffith DE, Brown B A, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996;23:983-9.
12. Panteix G, Guillaumond B, Harf R, et al. In-vitro concentration of azithromycin in human phagocytic cells. J Antimicrob Chemother 1993;31(suppl E):1-4.
13. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(suppl A):73-82.
14. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990;25(suppl A):39-47.